Email updates

Keep up to date with the latest news and content from BMC Cardiovascular Disorders and BioMed Central.

Open Access Highly Accessed Research article

EDTA chelation therapy for cardiovascular disease: a systematic review

Dugald MR Seely12*, Ping Wu23 and Edward J Mills4

Author Affiliations

1 Canadian College of Naturopathic Medicine, Toronto, Canada

2 Institute of Medical Science, University of Toronto, Toronto, Canada

3 London School of Hygiene and Tropical medicine, University of London, UK

4 Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Canada

For all author emails, please log on.

BMC Cardiovascular Disorders 2005, 5:32  doi:10.1186/1471-2261-5-32

Published: 1 November 2005

Abstract

Background

Numerous practitioners of both conventional and complementary and alternative medicine throughout North America and Europe claim that chelation therapy with EDTA is an effective means to both control and treat cardiovascular disease. These claims are controversial, and several randomized controlled trials have been completed dealing with this topic. To address this issue we conducted a systematic review to evaluate the best available evidence for the use of EDTA chelation therapy in the treatment of cardiovascular disease.

Methods

We conducted a systematic review of 7 databases from inception to May 2005. Hand searches were conducted in review articles and in any of the trials found. Experts in the field were contacted and registries of clinical trials were searched for unpublished data. To be included in the final systematic review, the studies had to be randomized controlled clinical trials.

Results

A total of seven articles were found assessing EDTA chelation for the treatment of cardiovascular disease. Two of these articles were subgroup analyses of one RCT that looked at different clinical outcomes. Of the remaining five studies, two smaller studies found a beneficial effect whereas the other three exhibited no benefit for cardiovascular disease from the use of EDTA chelation therapy. Adverse effects were rare but those of note included a few cases of hypocalcemia and a single case of increased creatinine in a patient on the EDTA intervention.

Conclusion

The best available evidence does not support the therapeutic use of EDTA chelation therapy in the treatment of cardiovascular disease. Although not considered to be a highly invasive or harmful therapy, it is possible that the use of EDTA chelation therapy in lieu of proven therapy may result in causing indirect harm to the patient.